Friday, 18 Aug 2017

You are here

Biosimilar Pricing Wars Have Begun

This week Merck announched the US launch of its biosimilar to infliximab, and announced it will discount 35% to the branded version's wholesale acquisition cost. This comes in stark contrast to Pfizer's Inflectra, another infliximab biosimilar, that was lauched with a disappointing 15% discount. Disappointing to those expecting greater savings with biosimilars being newly launched.

Despite the approval of four anti-TNF biosimilars in 12 months, their introduction into the U.S. market has been slow and - until now - with paultry discounts compared to their introduction throughout Europe, where discounts averaged 50% and were as high as 70% (compared to the price of Remicade).

Merck has priced Renflexis at a deeper discount to Remicade (Janssen) and Inflectra (Pfizer). Renflexis will have an introductory wholesale acquisition cost (WAC) of $753.39. The WAC of Remicade was $1,167.82 and Inflectra (infliximab-dyyb) was $946.28 according to Red Book July 24.  WACs do not include discounts that may be paid on the products.

Renflexis was developed by Samsung Bioepis and is being marketed by Merck in the U.S. Renflexis was approved by the FDA on April 21 for the following indications:  Crohn's, pediatric Crohn's disease, rheumatoid arthritis, psorisis, psoriatic arthritis and ankylosing spondylitis.

Sales of Remicade did drop 14% year over year in the second quarter, but J&J chalked much of that decline up to the roughly $170 million in rebate adjustments in the same period last year.

The pricing schemes are unknown for the biosimilars to follow, including Sandoz's Erelzi (etanercept) and Amgen's Amjevita (adalimumab). 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Uveitis Events Reduced with Select TNF Inhibitors

Uveitis may occur in up to 40% of spondyloarthritis patients. Metanalyses have shown that treatment with tumour necrosis factor-α inhibitor may reduce the rates of anterior uveitis. A multicenter study from Sweden and Norway has confirmed that amongst TNFi, adalimumab and infliximab offer better protection against AU than etanercept.

No Increase in Malformations with Etanercept Use During Pregnancy

While there are several reports detailing uncontrolled, observational results of biologic use during pregnancy, most are hampered by low numbers, incomplete data and too small a sample to make reliable judgements regarding the teratogenicity.  A company sponsored claims data analysis has shown that etanercept exposure during pregnancy was not associated with an increase in major congenital malformations (MCMs).

Withdrawal of TNF Inibitors Fails in Most RA Patients

The 12 month POET study analyzed 817 rheumatoid arthritis (RA) patients who achieved remission or low disease activity (LDAS) for ≥6 months and then randomized 2:1 to stopping or continuing their TNF inhibitor. They found that stopping TNFi had significantly negative consequences in the negative short-term, with fewer long-term negative consequences to drug cessation.

Golimumab Fails in Polyarticular Juvenile Arthritis

Treatment options for children with active polyarticular juvenile idiopathic arthritis (polyJIA) have lagged behind that seen with adult rheumatoid arthritis. Excluding new biosimilar indications, there are 9 currently approved biologics for adult RA, but only 5 of these have been approved for use in polyarticular JIA (pJIA) - abatacept, tocilizumab, etanercept, infliximab, and adalimumab.

Inflammatory Arthritis Stable after Switch to Biosimilar Infliximab

The DANBIO registrys has demonstrated that switching from infliximab (Remicade) to biosimilar CT-P13 (Inflectra in the U.S., Remsima in Europe) does not appear to have any negative effect on inflammatory arthritis disease activity, Danish researchers reported.